Strategic Use of Aureomycin® in Treating
Bovine Respiratory Disease
Introduction
Aureomycin (chlortetracycline) in the feed has been utilized to control bovine respiratory disease (BRD) for many
years. Previously, the approved dosage for controlling
bacterial pneumonia was 350 mg/head/day. On February
16, 1996, as a result of the Drug Efficacy Study
Implementation (DESI) program, Aureomycin received a
new approved indication for use in calves, beef and non-
lactating dairy cattle: 10 mg/lb body weight for not more
than 5 days for treatment of bacterial enteritis caused by
Escherichia coli and bacterial pneumonia caused by
Pasteurella multocida organisms susceptible to chlortetracycline. As a result of this new claim, Aureomycin can be
utilized at strategic times to treat BRD.
Bovine respiratory disease accounts for 65-79% of the
morbidity
1 and 44-72% of the
mortality
1,2 of feedlot cattle.
While fatality rates represent significant economic loss,
diminished returns due to decreased performance (ADG
and FE) associated with BRD may well exceed those due
to mortality. Wittum, et al.
3
found that lung lesions detected at slaughter of
finished cattle were associated with a
reduced ADG of 0.167 lb (0.076 kg) during the feeding
period. Thus, any management practice that decreases
BRD at the feedlot represents a large financial gain.
Impractical to Depend on Immunization Alone
Most feedlot cattle are processed on arrival, but many still
experience BRD before receiving adequate time to
respond to respiratory vaccines. Consequently, control of
BRD at the feedlot must begin with management practices
conducted prior to arrival. The most cost effective
approach would be to wean calves and administer respiratory
vaccines at the ranch, allowing development of immunity
before exposure to pathogens at the feedlot.
Unfortunately, the majority of calves arriving at feedlots
have not received the immunizations needed for BRD
control. In a cow/calf audit of Southeastern US and
overall U.S. on-farm management procedures conducted by
USDA:APHIS:VS: National Animal Health Monitoring
Service (NAHMS), less than 23% of all Southeastern
calves compared to less than 36% of all U.S. calves were
immunized on-farm for IBR, BVD,
H. somnus,
PI
3, and BRSV.
4 Pasteurella, a pathogen that accounts for most
respiratory deaths in feedlots, received even less attention,
with less than 16% of all U.S. calves receiving a
Pasteurella vaccine prior to shipment to a
feedlot or other operation (Table 1).
Data Shows Efficacy of Aureomycin vs. BRD
Administering antibiotics prior to shipment to the feedlot
has also been utilized in an effort to reduce BRD. Texas
A&M, through the Ranch-to-Rail program, conducted studies over two years to determine the impact Aureomycin
might have on feedlot BRD when administered on the
ranch prior to shipment.
5
Five days before shipment, the
calves on each ranch were gate cut into two groups of
approximately equal size. One group of calves remained
on the normal feeding program for the ranch. The other
group of calves was fed a supplemental feed containing
Aureomycin. The feed was also fortified with vitamins, A
and E, potassium, copper, zinc, and selenium. Daily feeding
rate provided Aureomycin at 1 g/100 lb body weight.
During the first five days at the feedyard in 1996-97, all
cattle received Aureomycin in the feed (intended dosage
1g/100 lb body weight). In 1997-98, the feedlot ration was
not medicated with Aureomycin. In these studies, cattle
receiving Aureomycin prior to shipment experienced fewer
BRD pulls, fewer treatments per head treated, and lower
hospital costs per head than the control group (Table 2).
Previous Ranch-to-Rail data suggests that sick cattle
receive a lower USDA quality grade than those never
treated. The lowered marbling score is in agreement with
these findings. Hospital costs per head treated included
only the invoiced cost of therapy and supportive treatment.
Carcass values were determined assuming a 730-lb
carcass with a Choice/Select spread of $5-10/cwt and
Choice/Standard spread of $8-13/cwt. The veterinary
medical costs and carcass values resulted in an advantage for
the Aureomycin cattle pre-shipment in both years
of $5.13 /head and $2.96 /head in for the 96-97 and 97-98
studies, respectively.
Assigning a "labor cost" to pull, treat, and return sick cattle
to the home pen has been estimated to range from $10 to
$40 per head or more. A $10 per head "labor cost" would
result in an additional advantage for the cattle receiving
pre-shipment Aureomycin of $1.32 /head in based upon
the results of these two studies. A $40 "labor cost" would
be $5.27 /head in Aureomycin advantage.
Those cattle considered medium to high risk for BRD on
arrival may receive mass medication with injectable antibiotics.
While this management practice has been shown to
reduce BRD morbidity, aspects such as antibiotic cost,
increased labor, stress on calves, and negative impacts
on quality assurance make its use less attractive. A 56day
study on 400 lb sale barn calves conducted by
Kansas State University compared the use of Micotil® 300
(tilmicosin phosphate) injection on arrival to Aureomycin
administered for the first 5 days after arrival, as well as
processing on arrival (day 1) to delayed processing (day
21).
6 In this study, Micotil (day 1 processing) and
Aureomycin (day 1 processing) reduced BRD morbidity
similarly compared to controls (no mass medication, day 1
processing). Cattle fed Aureomycin responded to BRD
treatment as well as cattle in the Micotil and control
groups. With respect to feed efficiency and average daily
gain, cattle that received Micotil and processed on day 1
were similar to cattle fed Aureomycin and processed on
day 1. The total cost of Aureomycin for the 5 days should
approximate $1.30 per calf, while the cost of Micotil in this
study was $7.50 per calf (Table 3).
Conclusions
Most bovine respiratory disease occurs during the initial
phases of feeding, but can occur following any period of
stress. The work of Wittum
3 suggests that cattle can suffer
from pneumonia without exhibiting clinical signs, and that
determining which cattle are suffering from BRD can be
difficult. Stressors, including weather changes, sorting,
and processing may induce subclinical pneumonia to
become clinical. Mass medication with Aureomycin at 10
mg/lb BW during times of stress effectively treats those
afflicted with clinical and subclinical pneumonia, thereby
reducing BRD and the subsequent performance losses.
Bovine respiratory disease can affect calves at various
times, and the strategic application of Aureomycin at 10
mg/lb BW for 5 days can be an effective management tool
in reducing its effects.
Literature Cited
- Vogel GJ, Parrott C. Mortality survey in feedyards. The incidence of death from digestive, respiratory, and other causes in
feedyards on the Great Plains. Comp Cont Ed Pract Vet 1994;
16:227-234.
- Edwards AJ. The effect of stressors like rumen overload and
induced abortion on BRD in feedlot cattle. Agri-Practice 1989;
10:10-15.
- Wittum TE, Woollen NE, Perino LJ, Littledike ET. Relationships
among treatment for respiratory tract disease, pulmonary lesions
evident at slaughter, and rate of weight gain in feedlot cattle.
JAVMA 1996; 209(4).
- USDA:APHIS:VS. National Animal Monitoring Service (NAHMS).
1993 Cow/Calf Health and Productivity Audit.
- Unpublished data. Personal communication, D. Clements, W.
Schroeder, D. Hausmann, and T. McCollum III, Texas A&M
University: Texas Agricultural Extension Service, Amarillo, TX.
- Kreikemeier K, Stokka G, Marston T. Influence of delayed processing and mass medication with either chlortetracycline or
tilmicosin phoshate on health and growth of highly stressed
calves. Kansas State University Agricultural Experiment Station
Rpt. of Progress 773: 23-27.
Aureomycin® is a registered trademark of Alpharma Inc.
Micotil® is a registered trademark of Elanco Animal Health
Copyright © 2002 Alpharma Inc.
Alpharma Inc.
One Executive Drive
Fort Lee, NJ 07024 USA
1-888-897-8657
Additional technical information is available at www.alpharma.com
Technical Bulletin No. CD 0325